Immune Thrombocytopenic Purpura | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2023

Immune thrombocytopenic purpura (ITP) is an autoimmune disease resulting in a low platelet count. Treatment of ITP involves the use of immunomodulators and corticosteroids as well as multiple therapies specifically approved for ITP. Thrombopoietin receptor agonists (TPO-RAs)—orally administered eltrombopag (Novartis’s Promacta / Revolade) and avatrombopag (Sobi’s Doptelet) and subcutaneously administered romiplostim (Amgen’s Nplate)—are key treatments for ITP. Rigel Pharmaceuticals / Grifols’ oral Tavalisse / Tavlesse (fostamatinib), a spleen tyrosine kinase inhibitor, is an option for treatment-refractory or unresponsive chronic ITP. Despite the availability of multiple therapies for ITP, effective treatments are needed for patients who are treatment-refractory or unresponsive to current therapies. Drugs that do not require chronic administration are also needed. Thus, ample commercial opportunity remains for pharmacotherapies with novel mechanisms of action as well as those with curative potential.

Questions answered

• What size are the ITP diagnosed prevalent populations (newly diagnosed, persistent, and chronic primary ITP) in the United States and EU5, and how will these populations change through 2032?
• How have the TPO-RAs and Tavalisse / Tavlesse been incorporated into the ITP treatment algorithm, and what is their commercial potential through 2032?
• What factors are driving and constraining market growth? Which new agents and classes of agents will emerge during the forecast period, and what impact will they have on the overall market?

Scope

• Geography: United States and EU5
• Primary research: Six country-specific interviews with thought-leading hematologists; supported by survey data collected for this study
• Epidemiology: Diagnosed incidence of ITP by country, diagnosed drug-treated prevalence of ITP by country, diagnosed prevalence of ITP by disease phase by country
• Forecast: Drug-level sales and patient share of key ITP therapies in 2022 and 2032
• Emerging therapies: Phase 3: 3 drugs; Phase 2: 3 drugs

Product description

Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Niche & Rare Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.